
Quarterly report 2025-Q4
added 01-08-2026
Neogen Corporation EPS Ratio 2011-2026 | NEOG
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Annual EPS Ratio Neogen Corporation
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -5.03 | -0.04 | -0.12 | 0.45 | 0.57 | 0.57 | 0.58 | 1.23 | 0.87 | 0.73 | 0.91 | 0.77 | 0.76 | 0.64 | 0.99 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.23 | -5.03 | 0.259 |
Quarterly EPS Ratio Neogen Corporation
| 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -0.07 | 0.17 | - | -0.05 | -2.1 | -0.06 | - | -0.01 | -0.02 | 0.01 | - | 0.04 | -0.19 | 0.05 | -0.23 | 0.05 | 0.1 | 0.16 | 0.26 | 0.13 | 0.15 | 0.15 | 0.3 | 0.12 | 0.15 | 0.14 | 0.31 | 0.28 | 0.31 | 0.29 | 0.31 | 0.29 | 0.33 | 0.23 | 0.33 | 0.31 | 0.22 | 0.2 | 0.29 | 0.26 | 0.24 | 0.25 | 0.24 | 0.25 | 0.21 | 0.24 | 0.21 | 0.24 | 0.17 | 0.22 | 0.17 | 0.33 | 0.19 | 0.19 | 0.29 | 0.28 | 0.22 | 0.26 | 0.22 | 0.26 |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 0.33 | -2.1 | 0.138 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
Agilent Technologies
A
|
3.98 | $ 116.92 | 2.67 % | $ 35.5 B | ||
|
Aspira Women's Health
AWH
|
-0.37 | - | -6.19 % | $ 10.5 M | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
BioNano Genomics
BNGO
|
-4.85 | $ 1.18 | 0.85 % | $ 6.43 M | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
CareDx, Inc
CDNA
|
-0.4 | $ 17.92 | 1.41 % | $ 955 M | ||
|
Exact Sciences Corporation
EXAS
|
-1.1 | - | - | $ 19.8 B | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Burning Rock Biotech Limited
BNR
|
-14.2 | $ 16.24 | 0.93 % | $ 175 M | ||
|
Co-Diagnostics
CODX
|
-35.2 | $ 4.4 | 101.83 % | $ 5.85 M | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
Interpace Biosciences
IDXG
|
5.55 | $ 1.98 | -0.63 % | $ 8.76 M | ||
|
Illumina
ILMN
|
-7.69 | $ 128.0 | 1.23 % | $ 20.4 B | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 25.19 | 1.45 % | $ 700 M | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
Laboratory Corporation of America Holdings
LH
|
10.5 | $ 274.72 | 2.06 % | $ 22.9 B | ||
|
Charles River Laboratories International
CRL
|
-2.91 | $ 175.07 | 3.26 % | $ 8.68 B | ||
|
Medpace Holdings
MEDP
|
15.6 | $ 520.65 | 2.39 % | $ 15 B | ||
|
Danaher Corporation
DHR
|
5.07 | $ 196.19 | 2.71 % | $ 140 B | ||
|
Motus GI Holdings
MOTS
|
-15.9 | - | -34.28 % | $ 263 K | ||
|
Myriad Genetics
MYGN
|
-3.95 | $ 4.77 | 0.63 % | $ 442 M | ||
|
National Research Corporation
NRC
|
50 | $ 17.26 | 1.29 % | $ 386 M | ||
|
Natera
NTRA
|
-5.57 | $ 210.83 | 0.75 % | $ 20.7 B | ||
|
Invitae Corporation
NVTA
|
-13.2 | - | - | $ 21.2 M | ||
|
Organovo Holdings
ONVO
|
-1.7 | - | -2.3 % | $ 19.4 M | ||
|
OpGen
OPGN
|
2.44 | - | -16.95 % | $ 1.54 M | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 15.83 | -0.5 % | $ 479 M | ||
|
Pacific Biosciences of California
PACB
|
-1.82 | $ 1.47 | 2.08 % | $ 441 M | ||
|
Guardant Health
GH
|
-3.32 | $ 92.84 | -0.49 % | $ 11.6 B | ||
|
PerkinElmer
PKI
|
2.07 | - | -0.91 % | $ 14.7 B | ||
|
QIAGEN N.V.
QGEN
|
1.96 | - | - | $ 10.6 B | ||
|
Psychemedics Corporation
PMD
|
-0.72 | - | -1.84 % | $ 15.3 M | ||
|
Personalis
PSNL
|
-1.37 | $ 6.33 | 2.59 % | $ 375 M | ||
|
Anixa Biosciences
ANIX
|
-0.34 | $ 2.73 | 1.49 % | $ 88.6 K | ||
|
Biomerica
BMRA
|
-2.16 | $ 2.15 | -0.46 % | $ 4.94 M | ||
|
Quotient Limited
QTNT
|
-1.21 | - | -11.32 % | $ 1.1 M | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 106.54 | -0.58 % | $ 8.79 B | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
Celcuity
CELC
|
-3.79 | $ 116.94 | 1.19 % | $ 5.47 B |